A20-Binding Inhibitor of NF-κB 1 Ameliorates Neuroinflammation and Mediates Antineuroinflammatory Effect of Electroacupuncture in Cerebral Ischemia/Reperfusion Rats

Xueling Zhou,1,2 Wenhao Lu,1,2 You Wang,3 Jiani Li,3 and Yong Luo1

1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
3Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Correspondence should be addressed to Yong Luo; luoyong1998@163.com

Received 31 July 2020; Revised 22 September 2020; Accepted 25 September 2020; Published 14 October 2020

Copyright © 2020 Xueling Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A20-binding inhibitor of NF-κB 1 (ABIN1) is an inhibitor of NF-κB and exerts anti-inflammatory effect. Electroacupuncture (EA) is considered as a neuroprotective strategy by inhibiting neuroinflammatory damage after cerebral ischemia. This study was performed to explore the role of ABIN1 and investigate whether the ABIN1 is involved in the mechanism of EA in cerebral ischemia/reperfusion (I/R) rats. Male Sprague-Dawley (SD) rats were subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) and received EA after reperfusion once a day. Lentivirus-mediated ABIN1 gene knockdown was used to detect the role of ABIN1 in neuroinflammation after I/R. ABIN1 expression, proinflammatory cytokine levels, microglial activation, neurological function, infarct volumes, and NF-κB activation were assessed. ABIN1 expression was elevated in the peri-infarct cortex and was further upregulated by EA. ABIN1 knockdown increased the levels of proinflammatory cytokines and activation of microglia, worsened neurological deficits, and enlarged the infarct volume. Moreover, ABIN1 was blocked to partially reverse the neuroprotective effect of EA, and this treatment weakened the ability of EA to suppress NF-κB activity. Based on these findings, ABIN1 is a potential suppressor of neuroinflammation and ABIN1 mediates the antineuroinflammatory effect of EA in cerebral I/R rats.

1. Introduction

Ischemic stroke accounts for 84.4% of all strokes, resulting in a high global burden [1]. With the development of endovascular therapy, the treatment of acute ischemic stroke has entered a new stage [2]. However, recanalization can lead to cerebral ischemia/reperfusion damage. Thus, neuroprotection combined with reperfusion therapy is an important next step in the development of ischemic stroke treatment [3, 4]. The pathological mechanism of cerebral ischemia/reperfusion (I/R) is complex. Excessive neuroinflammation after cerebral I/R is one of the main culprits for aggravating brain damage [5–7], which has been considered as a potential therapeutic target [4, 8]. NF-κB acts as a “molecular switch” in ischemic stroke, promoting the initiation and amplification of the inflammatory cascade [9]. The most common dimeric form of NF-κB is p65/p50, and the dimer binds to inhibitor of kappa B (IκB) and is localized in the cytoplasm in the resting state. Upon stimulation by cerebral ischemia, IκB proteins are phosphorylated by the inhibitor of kappa B kinase (IKK) and degraded, allowing NF-κB to enter the nucleus and promote the expression of a series of proinflammatory cytokines [9–11].

A20-binding inhibitor of NF-κB 1 (ABIN1) is a physiological inhibitor of NF-κB that binds the Lys63 and Met-1 polyubiquitin chains with high affinity [12, 13]. As an adaptor protein of A20, ABIN1 promotes the deubiquitination of molecules upstream of NF-κB and inhibits NF-κB...
activation [14, 15]. ABIN1-deficient mice die during embryogenesis and the mice that survive exhibit immune cell activation and develop a progressive, lupus-like inflammatory disease [16, 17]. Notably, ABIN1 acts as an inhibitor of inflammation in various inflammatory diseases, such as hepatic I/R, asthma, systemic lupus erythematosus, psoriasis, and osteoarthritis [18–22]. However, the role of ABIN1 in neuroinflammatory damage after cerebral I/R has not been reported.

Electroacupuncture (EA) is a product of modern technology that adds electrical stimulation to acupuncture, which is characterized by a low cost, few side effects, and controllable parameters. EA regulates the immune response and restores homeostasis, which may underlie its use as a treatment for various inflammation-related diseases [23–25]. Furthermore, EA is a widely used treatment for ischemic stroke and has achieved good results [26–28]. The neuroprotective effect of EA is closely related to the inhibition of NF-κB [29–31]; however, the specific regulatory mechanism of EA has not been completely clarified. As shown in our previous studies, EA inhibits IκBα phosphorylation and prevents the nuclear translocation of NF-κB p65 by upregulating the neuronal deubiquitinating enzyme A20 to ultimately improve the neurological deficits in middle cerebral artery occlusion/reperfusion (MCAO/R) rats [32]. Interestingly, ABIN1 is an important member of the A20 complex and may also be regulated by EA. Considering the fact that ABIN1 plays a crucial role in inhibiting NF-κB-related inflammatory responses, EA may inhibit NF-κB activation and exert neuroprotective effect via upregulating ABIN1 expression in cerebral I/R rats. Therefore, in the present study, we initially explored the effect of ABIN1 on neuroinflammatory damage in a MCAO/R rat. Then, the possible mechanism by which EA regulates the expression of ABIN1 to inhibit NF-κB activation was investigated.

2. Methods

2.1. Animals. Healthy Sprague-Dawley (SD) rats weighing 280–300 g were purchased from Experimental Animal Center of Chongqing Medical University (Chongqing, China). Animals were maintained in a specific pathogen-free (SPF) room (12 h light/dark cycle, 22 ± 2°C, 60–70% humidity). Rats were allowed for free access to food and water. Rats were kept for a week to acclimatize before the experiment. All animal experimental procedures were approved by the Ethics Committee for Animal Experimentation of Chongqing Medical University (number SYXK(Yu) 2018-0003) and were performed in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals.

In the first study, rats were randomly divided into 4 groups: sham group, MCAO/R group, MCAO/R + EA group, and MCAO/R + sham EA group to investigate the expression of ABIN1 in the peri-infarct cortex.

The second study elucidated the effect of ABIN1 on neuroinflammatory damage after I/R using sham group, MCAO/R group, MCAO/R + LV-Scramble group, and MCAO/R + LV-shABIN1 group.

The third study explored whether ABIN1 was involved in the antineuroinflammatory mechanism of EA using MCAO/R group, MCAO/R + EA group, MCAO/R + EA + LV-Scramble group, and MCAO/R + EA + LV-shABIN1 group.

2.2. Establishment of the MCAO/R Model. A total of 208 rats were used in this experiment, including 17 rats that were excluded due to death (n = 14) or unsuccessful induction of ischemia (n = 3). SD rats underwent MCAO/R as previously described [33]. Briefly, rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.). A nylon monofilament with a silicon-coated rounded tip was inserted to block the right middle cerebral artery. After 2 h of ischemia, the nylon monofilament was removed to induce reperfusion. Rats were detected by a laser Doppler flowmetry (PeriFlux 5000, Perimed AB, Sweden), and regional cerebral blood flow decreased to 20% and recovered to >80% of baseline, indicating the successful establishment of the MCAO/R model. The rats in the sham group underwent the same operation, except that the monofilament was not inserted to block the middle cerebral artery. Rat rectal temperature was maintained at 37 ± 0.5°C with an electrothermal pad.

2.3. Intracerebral Lentivirus Injection. Lentiviruses containing the ABIN1 shRNA (LV-shABIN1) for ABIN1 knockdown and control shRNA (LV-Scramble) were supplied by Genechem (Shanghai, China). Two weeks prior to the establishment of the MCAO/R model, the right cortex of each rat was injected with the lentiviruses. The injection sites were as follows: site 1, A-P: 1.0 mm; M-L: 2.0 mm; D-V: 1.2 mm, and site 2, A-P: 3.0 mm; M-L: 1.5 mm; D-V: 1.2 mm [34]. A total of 2.5 μl of LV-shABIN1 or LV-Scramble were injected into each site.

2.4. EA Treatment. Immediately after reperfusion, the rat was treated with EA once a day until sacrifice. EA was performed as described previously [32] and acupuncture needles were inserted at Baihui (GV 20), Hegu (LI 4), and Taichong (LR 3) (Figure 1) and connected with EA instrument (Model no. SDZ-III, Hwato, China). To construct a circuit, two electrodes were connected, respectively, to the needle at GV 20 and the left ear (nonacupoint). Another two electrodes were connected, respectively, to the needle at LI 4 and LR 3. The stimulation parameters were intensity of 1 mA and a frequency of 20 Hz for 5 min followed by 2 Hz for 30 min. In the sham EA group, needles were affixed to the acupoints without skin penetration, and the animals did not receive electrical stimulation [35].

2.5. Evaluation of the Neurological Function. At 72 h before and 24, 48, and 72 h after cerebral I/R, each rat was assessed with the Modified Neurological Severity Score (mNSS) and Modified Sticky-Tape Test (MST) by an observer who was blinded to the experiments. The mNSS is a comprehensive scoring system that includes motor, balance, sensory, and reflex tests and is graded on a scale of 0 (normal) to 18 (maximal deficit) points [36]. The Modified Sticky-Tape Test
2.6. Measurement of the Cerebral Infarct Volume. Rats were euthanized with an overdose of sodium pentobarbital (150 mg/kg, i.p.). After sacrifice, brains were cut into 2 mm thick serial coronal slices and immersed in 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C for 15 min in the dark. Images were acquired with a camera and analyzed with ImageJ software. The infarct volume was presented as a percentage of the intact hemisphere.

2.7. Real-Time Quantitative PCR (RT-qPCR). As shown in Figure 2(a), the pale area was considered to be the infarct core. Strips of tissue (2 mm thick) surrounding the infarct core were considered as the peri-infarct tissue and dissected for RT-qPCR and western blot analysis [38]. Total RNA was extracted from the peri-infarct cortex using Trizol (TaKaRa, Japan). Then, cDNAs were synthesized using a PrimeScript RT reagent kit with gDNA Eraser (TaKaRa) and were used as a template for RT-qPCR, which was conducted in a CFX96 Real-Time PCR Detection System (Bio-Rad Co., USA) with SYBR Green. The following primer sequences were used (5' to 3'): GAPDH: forward: AAGTTCACGGCA-CAGTCAAGG and reverse: ACGCCAGTA-GACTCCAAGCAGAT, and ABIN1: forward: TCGGGCTGAAGGGAAAAATACA and reverse: CAAAG-GAGACCAAGGAGGAG. The results were normalized to the levels of the housekeeping gene GAPDH.

2.8. Western Blot Analysis. Proteins were extracted from the peri-infarct cortex using RIPA buffer (Beyotime, China). A cytoplasmic/nuclear protein extraction kit (Beyotime) was used to extract cytoplasmic and nuclear proteins. Western blot was performed as described previously [39]. Briefly, proteins were separated on 10% gels and transferred to PVDF membranes. After blocking with 5% skim milk, membranes were incubated with the primary antibodies at 4°C overnight. The following primary antibodies against specific proteins were used: ABIN1 (#4664, Cell Signaling Technology, USA, 1:1000), A20 (#5630, Cell Signaling Technology, USA, 1:1000), NF-κB p65 (#8242, Cell Signaling Technology, USA, 1:1000), IkBa (18220-1-AP, Proteintech, USA, 1:000), phospho-IkBa (Ser32) (#2859, Cell Signaling Technology, USA, 1:1000), GAPDH (10494-1-AP, Proteintech, USA, 1:1000), and histone H3 (#3638, Cell Signaling Technology, USA, 1:1000). Membranes were washed with TBST and immersed in the secondary antibodies at 37°C for 1 h. After washes with TBST, immunoreactive bands were detected using WesternBright ECL (Advansta, USA). Membranes were scanned and analyzed using a Fusion FX5 analysis system (Vilber Lourmat Fusion FX 7 Spectra, France).

2.9. ELISA. The peri-infarct cortex was collected 24 h after reperfusion, and the concentrations of TNF-α, MCP-1, and IL-1β were assayed using ELISA kits (nos. EK0526, EK0902, and EK0393, respectively, BOSTER, China).

2.10. Immunofluorescence Staining. Brain tissues were fixed, dehydrated, and then cut into coronal sections at a thickness of 10 μm. Sections were permeabilized with 0.3% Triton X-100. Then, brain slices were blocked with 5% donkey or goat serum for 1 h and incubated overnight at 4°C with primary antibodies: ABIN1 (bs-9568R, Bioss, China, 1:50), NeuN (MAB377, Millipore, Germany, 1:200), A20 (3A11G6, Proteintech, USA, 1:100), Iba-1 (NB100-1028, Novus, USA, 1:50), and GFAP (BM0055, Boster, China, 1:100). Then, the following fluorescently labeled secondary antibodies were incubated with the sections at 37°C for 1 h in the dark: CoraLite594-goat anti-rabbit (SA00003-3, Proteintech, France), or normal rat IgG was added to each sample. After washes with TBST, immunoreactive bands were detected using WesternBright ECL (Advansta, USA). Membranes were scanned and analyzed using a Fusion FX5 analysis system (Vilber Lourmat Fusion FX 7 Spectra, France).

2.11. Coimmunoprecipitation. The peri-infarct cortex was homogenized in IP lysis buffer (Beyotime, China) to extract the proteins. One microgram of anti-ABIN1 antibody (#4664, Cell Signaling Technology), anti-A20 antibody (#5630, Cell Signaling Technology), or normal rat IgG was added to each milligram of total protein in the supernatants, and the samples were rotated at 4°C overnight. Forty microliters of protein A/G agarose beads was mixed with the supernatants and rotated at 4°C for 2 h. The beads were washed with lysis buffer and then eluted with 40 μl of SDS loading buffer. The supernatants were collected for western blot.

2.12. Statistical Analyses. All data were analyzed using SPSS 21.0 and graphed using GraphPad Prism 8.0 and expressed as the means ± SEMs. The differences of cellular localization of ABIN1 were assessed using the unpaired t-test. All other quantitative data were analyzed using one-way ANOVA. P < 0.05 was considered statistically significant.
Figure 2: ABIN1 expression in the peri-infarct area at different time points. (a) The core and peri-infarct areas of a MCAO/R rat. (b–d) RT-qPCR and western blot were used to, respectively, detect the levels of the ABIN1 mRNA and protein in the peri-infarct cortex at 6 h, 12 h, 24 h, 48 h, and 72 h after reperfusion (n = 5 rats per group). The expression of ABIN1 was normalized to GAPDH. (e) ABIN1 (red) and DAPI (blue) immunofluorescence staining present the distribution of ABIN1 at 24 h after reperfusion (n = 3 rats per group). Scale bar = 50 μm. (f) Column chart presenting the ABIN1+ cell counts in the four groups (*P < 0.05 and **P < 0.01 compared to the sham group; #P < 0.05 and ##P < 0.01 compared to the MCAO/R group).
3. Results

3.1. ABIN1 Expression Is Induced in MCAO/R Rats. We measured the levels of the ABIN1 mRNA and protein in the peri-infarct cortex at 6 h, 12 h, 24 h, 48 h, and 72 h after reperfusion. The expression of the ABIN1 mRNA and protein peaked in the MCAO/R group at 24 h after reperfusion and then gradually decreased (Figures 2(b)–2(d)). The ABIN1 mRNA and protein were expressed at higher levels in the MCAO/R group than in the sham group from 12 h to 72 h (Figures 2(b)–2(d)). Moreover, compared with the MCAO/R group, EA further increased the expression of the ABIN1 from 6 h to 72 h (Figures 2(b)–2(d)). In addition, ABIN1 was detected using immunofluorescence staining at 24 h after reperfusion (Figures 2(e) and 2(f)). Compared to the sham group, the number of ABIN1+ cells in the peri-infarct cortex was significantly increased in the MCAO/R group (Figures 2(e) and 2(f)). Moreover, the number of ABIN1+ cells was further increased in rats receiving EA (Figures 2(e) and 2(f)). A significant difference in ABIN1 expression was not observed between the MCAO/R group and MCAO/R + sham EA group (Figures 2(b)–2(f)).

3.2. The Distribution of ABIN1 in the Peri-Infarct Cortex. ABIN1 has been described as an NF-κB suppressor through interacting with A20 [12]; to further verify the interaction between A20 and ABIN1 in the peri-infarct cortex, the immunofluorescence staining and coimmunoprecipitation were performed. The immunofluorescence staining revealed numerous ABIN1+ and A20+ cells in the peri-infarct cortex 24 h after reperfusion, and A20 and ABIN1 were colocalized in the cytoplasm (Figure 3(a)). The coimmunoprecipitation results further suggested that ABIN1 and A20 bind to each other in the peri-infarct cortex at 24 h after reperfusion (Figure 3(b)).

Next, the cellular localization of ABIN1 in the peri-infarct cortex 24 h after reperfusion was evaluated using double immunofluorescence labeling. ABIN1 was colocalized with NeuN (a neuron marker) and Iba-1 (a microglia marker) but not with GFAP (an astrocyte marker) (Figure 3(c)). Moreover, ABIN1 NeuN+ cells accounted for 70.22 ± 1.71% of ABIN1+ cells, and ABIN1 Iba-1+ cells accounted for 26.83 ± 2.75% of ABIN1+ cells in the peri-infarct cortex (Figures 3(c) and 3(d)). These results indicated that neurons and microglia were the cellular source of ABIN1 in the peri-infarct cortex.

3.3. ABIN1 Knockdown Increases Proinflammatory Cytokines Production and Microglial Activation. ABIN1 was silenced by a cortical injection of LV-shABIN1 to further explore the role of ABIN1 in neuroinflammation after I/R. First, the levels of the ABIN1 mRNA and protein were measured at 24 h after reperfusion to ensure the effectiveness of ABIN1 knockdown. The expression of ABIN1 was significantly reduced in the MCAO/R + LV-shABIN1 group (Figures 4(a) and 4(b)), indicating that ABIN1 was successfully silenced.

Then, we examined the production of proinflammatory factors and microglial activation using ELISA and immunofluorescence staining, respectively. Typical proinflammatory factors TNF-α, IL-1β, and MCP-1 were produced at higher levels in the MCAO/R group than in the sham group (Figure 4(c)). Higher levels of these cytokines were detected in the MCAO/R + LV-shABIN1 group than in the MCAO/R group (Figure 4(c)). The levels of these proinflammatory factors were not significantly different between the MCAO/R + LV-scramble group and the MCAO/R group (Figure 4(c)).

The morphology of microglia is closely related to their biological functions. Resting microglia are hyperramified. Activated microglia are characterized by enlarged cell bodies with short and thick processes and round and rod-like cell bodies, and some even exhibit an ameba-like cell bodies [40]. We evaluated the activation of microglia by quantifying the number of endpoints per cell and the length of cell processes, which may serve as indicators of neuroinflammation [41, 42]. Immunofluorescence staining for Iba-1 was used to detect microglia in the peri-infarct cortex at 24 h after I/R. The microglia in the sham group exhibited the resting state phenotype (hyperramification) (Figure 4(d)). As shown in Figures 4(d)–4(f), the number of endpoints per cell and the length of cell process were decreased in the MCAO/R group compared with the sham group, indicating that more activated microglia were present in the MCAO/R rats. Moreover, the number of endpoints per cell and the length of cell process were reduced in the MCAO/R + LV-shABIN1 group compared with the MCAO/R group, suggesting that blockade of ABIN1 expression enhanced microglial activation (Figures 4(d)–4(f)). Significant differences were not observed between the MCAO/R + LV-scramble group and the MCAO/R group (Figures 4(d)–4(f)).

3.4. ABIN1 Knockdown Exacerbates the Neurological Deficits and Enlarges the Infarct Volume. The mNSS and MST were used to assess the neurological function of rats 72 h before and 24, 48, and 72 h after cerebral I/R. At 72 h before reperfusion, the neurological function of rats was normal and no significant differences were observed among the groups (Figures 5(a) and 5(b)). The mNSS and MST ratio of the MCAO/R group were worse than the sham group at 24, 48, and 72 h after I/R (Figures 5(a) and 5(b)). Compared with the MCAO/R group, the neurological deficits of the MCAO/R + LV-shABIN1 group were increased significantly at 72 h but not at 48 h or 24 h (Figures 5(a) and 5(b)). The neurological deficits of the MCAO/R + LV-scramble group were not different from the MCAO/R group at 24, 48, and 72 h after I/R (Figures 5(a) and 5(b)). The infarct volume was assessed using TTC staining at 72 h after reperfusion. The cerebral infarct volume did not differ significantly between the MCAO/R + LV-scramble group and the MCAO/R group but was expanded in the MCAO/R + LV-shABIN1 group (Figures 5(c) and 5(d)).

3.5. ABIN1 Knockdown Weakens the Antineuroinflammatory Effect of EA to Some Extent. The concentrations of TNF-α, IL-1β, and MCP-1 in the peri-infarct cortex were detected at...
24 h after reperfusion using ELISA to determine the effect of ABIN1 knockdown on the antineuroinflammatory effect of EA. The levels of these proinflammatory cytokines were significantly decreased in the MCAO/R + EA group compared with the MCAO/R group (Figure 6(a)). In addition, ABIN1 knockdown impaired the antineuroinflammatory effect of EA, since higher levels of TNF-α, IL-1β, and MCP-1 were detected in the MCAO/R + EA + LV-shABIN1 group than in the MCAO/R + EA group (Figure 6(a)). The MCAO/R + EA + LV-scramble and MCAO/R + EA groups displayed similar levels of these cytokines (Figure 6(a)). Furthermore, the results of Iba-1 immunofluorescence staining in the peri-infarct cortex at 24 h after reperfusion indicated that the MCAO/R + EA group had more endpoints per cell and longer cell processes than the MCAO/R group; however, ABIN1 knockdown in the MCAO/R + EA + LV-shABIN1 group promoted microglial activation (Figures 6(b)–6(d)). Microglia activation was not significantly different between the MCAO/R + EA + LV-scramble group and MCAO/R + EA group (Figures 6(b)–6(d)).

3.6. ABIN1 Knockdown Partially Inhibits the Neuroprotective Effect of EA. The mNSS and MST of rats in the four groups were assessed at 72 h before and 24, 48, and 72 h after reperfusion. At 72 h before reperfusion, the neurological function of rats was normal and no significant differences were observed among groups. The neurological impairments observed in rats in the MCAO/R + EA group were significantly improved at 72 h but not 24 and 48 h after reperfusion compared with rats in the MCAO/R group (Figures 7(a) and 7(b)). Rats in the MCAO/R + EA + LV-shABIN1 group exhibited worse neurological deficits than rats in the MCAO/R + EA group at 72 h after reperfusion (Figures 7(a) and 7(b)). The mNSS and MST of rats in the MCAO/R + EA group were similar to rats in the MCAO/R + EA + LV-scramble group (Figures 7(a) and 7(b)). TTC staining at 72 h after reperfusion revealed a smaller infarct volume in the MCAO/R + EA group than in the MCAO/R group (Figures 7(c) and 7(d)). However, in the MCAO/R + EA + LV-shABIN1 group, ABIN1 knockdown increased the infarct volume compared with the MCAO/R + EA group (Figures 7(c) and 7(d)). The infarct volume did not significantly differ between the MCAO/R + EA + LV-scramble group and the MCAO/R + EA group (Figures 7(c) and 7(d)). Based on these results, EA exerted a protective effect on the brain after I/R, but ABIN1 knockdown weakened the effect of EA.

3.7. EA Inhibits NF-κB Activation by Upregulating ABIN1. As mentioned above, NF-κB plays a key role in focal cerebral I/R-induced neuroinflammation. To further explore whether ABIN1 mediated EA induced inhibition of NF-κB
Figure 4: ABIN1 knockdown increases proinflammatory cytokine production and microglial activation. (a-b) Levels of the ABIN1 mRNA and protein were detected 24 h after reperfusion using RT-qPCR and western blot, respectively, to confirm the efficiency of ABIN1 gene knockdown (n = 5 rats per group). (c) ELISA was used to detect the concentrations of TNF-α, IL-1β, and MCP-1 in the peri-infarct cortex at 24 h after reperfusion (n = 5 rats per group). (d) Microglial morphology was observed using immunofluorescence staining for Iba-1 (green) in the peri-infarct cortex at 24 h after reperfusion (n = 3 rats per group). Scale bar = 50 μm. (e and f) Quantification of microglia process endpoints and cell and process lengths/cell (∗∗P < 0.01 compared to the sham group; ##P < 0.01 compared to the MCAO/R group).
activation, levels of the ABIN1, p-IκBα, IκBα, and nuclear/cytoplasmic NF-κB p65 proteins were measured in the peri-infarct cortex at 24 h after reperfusion using western blot and the nuclear translocation of NF-κB p65 was observed using immunofluorescence staining. EA significantly increased the level of the ABIN1 protein and decreased the p-IκBα/IκBα ratio and NF-κB p65 nuclear translocation compared with the MCAO/R group (Figures 8(a)–8(d)). However, ABIN1 knockdown diminished the anti-inflammatory effect of EA as observed that p-IκBα/IκBα ratio was increased and NF-κB p65 nuclear translocation was enhanced in the MCAO/R + EA + LV-shABIN1 group compared with the MCAO/R + EA group (Figures 8(a)–8(d)). The levels of these proteins were not significantly different between the MCAO/R + EA + LV-scramble group and the MCAO/R + EA group (Figures 8(a)–8(d)). Hence, EA may inhibit NF-κB activation by upregulating ABIN1 expression.

4. Discussion

EA plays a beneficial role in ischemic stroke, but the mechanism of EA needs further research [43]. In the present study, we showed for the first time that ABIN1 was induced in MCAO/R rats. ABIN1 knockdown aggravated cerebral I/R injury by promoting activation of microglia and releasing proinflammatory factors (TNF-α, IL-1β, and MCP-1). Moreover, upregulation of ABIN1 expression was essential for EA to inhibit NF-κB related neuroinflammatory damage after cerebral I/R.

ABIN1 mRNA is highly expressed in human peripheral lymphocytes, skeletal muscle, and spleen, and its polymorphisms are associated with autoimmune diseases [15]. We assessed the expression of ABIN1 in the early phase of cerebral I/R. The ABIN1 mRNA and protein were expressed in the cerebral cortex of the sham group, indicating that ABIN1 is constitutively expressed in the cerebral...
cortex under normal conditions. In addition, ABIN1 expression was induced in the peri-infarct cortex, peaking at 24 h and then gradually decreasing. NF-κB is strongly activated during cerebral ischemia in cells such as neurons, microglia, astrocytes, and endothelial cells [11, 44]. The expression of some negative regulators of NF-κB is regulated
by NF-κB to prevent its continuous activation [13, 45]. A20 is one of these negative regulators. A20 is expressed at low levels in most cells under physiological conditions, but its expression is rapidly induced upon the activation of NF-κB [46]. Similarly, ABIN1 expression is also regulated by NF-κB. The human ABIN1 gene promoter contains an NF-κB response element, and its promoter activity is regulated by NF-κB [47]. The expression of the ABIN1 mRNA is upregulated in various cell types with NF-κB activation [15]. Thus, the increase in ABIN1 expression observed in the early stage of focal cerebral I/R may be attributed to the activation of NF-κB, thus forming a negative feedback loop.

The A20 complex is expressed at higher levels in neurons than in glial cells [45, 48]. Similarly, as shown in our previous study, A20 is mainly expressed in neurons in the cortex of MCAO/R rats [32]. In the current study, we found that ABIN1 and A20 colocalized in the cytoplasm and interacted with each other in the peri-infarct cortex at 24 h. Besides, we determined the spatial distribution of ABIN1 in the peri-infarct cortex in MCAO/R rats for the first time. ABIN1 was prominently localized in neurons, followed by microglia, and no expression was observed in astrocytes at 24 h after I/R. The mechanism underlying the predominant expression of ABIN1 in neurons is unclear, but this differential distribution may be a protective strategy for neurons due to their high sensitivity to ischemia and hypoxia and limited tolerance to excessive activation of NF-κB and neuro-inflammation after I/R [49].

In the early phase of cerebral I/R, damaged neurons release cytokines, chemokines and damage-associated proteins, which further activate NF-κB, leading to the continuous activation of this pathway. To prevent such a cycle, ABIN1 and A20 may act as negative regulators by forming a feedback loop.
Figure 8: EA prevents NF-κB activation by upregulating ABIN1 expression. (a-c) The levels of ABIN1, p-1xBa, 1xBa, nuclear NF-κB p65, and cytoplasmic NF-κB p65 proteins in the peri-infarct cortex at 24 h after reperfusion were detected using western blot. GAPDH served as the internal reference for total and cytoplasmic proteins, and histone H3 served as the internal reference for nuclear proteins (n = 5 rats per group). (d) The nuclear translocation of NF-κB p65 was observed with immunofluorescence staining in the peri-infarct area at 24 h after reperfusion (n = 3 rats per group). Scale bar = 20 μm. Column chart presenting the NF-κB p65+ cell counts in the four groups (* P < 0.05 and ** P < 0.01 compared to the MCAO/R group; # P < 0.05 and ## P < 0.01 compared to the MCAO/R + EA group).
molecular patterns; microglia, the first line of defense in the brain, are activated within minutes after receiving signals from neurons [50, 51]. In the penumbra, proinflammatory microglia gradually dominate the response, resulting in an imbalance between proinflammatory and anti-inflammatory effects [52, 53]. Excessive proinflammatory factors such as TNF-α, IL-1β, and MCP-1 contribute to neuron death and the aggravation of brain damage [6, 54]. ABIN1 knockdown used lentivirus-mediated delivery of shABIN1 to investigate the effect of ABIN1 on focal cerebral I/R-induced neuroinflammation. ABIN1 knockdown increased microglial activation and proinflammatory factor production (TNF-α, IL-1β, and MCP-1), worsened neurological function, and enlarged the infarct volume. Thus, ABIN1 may confer neuroprotection by reducing inflammatory damage during cerebral I/R. However, in the MCAO/R group, the upregulation of endogenous ABIN1 expression by focal cerebral I/R is insufficient to resist strong neuroinflammation; thus, the increase in ABIN1 expression may represent a promising therapeutic strategy to alleviate neuroinflammation after cerebral I/R.

EA is a supplemental and alternative treatment for ischemic stroke that is recommended by the World Health Organization [26]. EA therapy requires a combination of specific acupoints and electrical stimulation. Acupoints GV 20, LI 4, and LR 3 exert the effects of tranquilization and resuscitation and are selected for treating ischemic stroke in traditional Chinese medicine [55, 56]. Our previous study showed that EA treatment at acupoints GV 20, LI 4, and LR 3 played a neuroprotective role in MCAO/R rats by suppressing NF-κB activation [31]. Subsequently, it was shown that deubiquitinating enzyme A20 was upregulated by EA to inhibit IκBα phosphorylation and prevent NF-κB p65 nuclear translocation [32]. As an adaptor protein of A20, ABIN1 has similar biological functions to A20. For example, A20- and ABIN1-deficient mice showed premature death and severe inflammation, and the SNPs of A20 and ABIN1 genes were closely related to autoimmune diseases [12, 13]. Thus, whether ABIN1 is involved in the mechanism of EA is of great interest to us. The current study revealed that EA treatment at acupoints GV 20, LI 4, and LR 3 increased the expression of ABIN1 in the peri-infarct cortex. Since sham EA is biologically inactive because of the absence of important EA elements, such as the insertion of needles into acupoints and electrical stimulation [57–60], the expression of ABIN1 in peri-infarct cortex was not altered by sham EA. Besides, we showed that EA inhibited IκBα phosphorylation, prevented NF-κB p65 nuclear translocation, suppressed neuroinflammation, and improved neurological deficits. However, the neuroprotective effect of EA was partially reversed by ABIN1 knockdown. Based on these results, it was suggested that ABIN1 was involved in the mechanism of EA in alleviating cerebral I/R inflammatory damage. As mentioned above, ABIN1 was predominantly localized in neurons in the peri-infarct cortex; thus EA may inhibit neuronal NF-κB activation by upregulating ABIN1 expression and eventually indirectly inhibit microglia aggregation and activation. Since some ABIN are also expressed in microglia, EA may reduce the production of proinflammatory factors by directly inhibiting NF-κB activation in microglia. Further research will address these hypotheses in vitro to determine the effect of ABIN1 expression levels on NF-κB activation in neurons and microglia, respectively.

5. Conclusion
In conclusion, ABIN1, which is induced in cerebral I/R, plays a neuroprotective role as an inflammatory suppressor. Furthermore, this study indicated that the EA-induced upregulation of ABIN1 expression may be an important mechanism by which EA blocks NF-κB activation to alleviate neuroinflammation after cerebral I/R.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure
These funding bodies were not involved in the design of the study or collection, analysis, interpretation of data, or writing of the manuscript.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (Grant no. 30470606), the National Natural Science Foundation of China Youth Fund Project (Grant no. 81403243), and the Chinese Medicine Science and Technology Project of Chongqing Municipal Health Bureau (Grant 2012-2-128).

References
[1] C. O. Johnson, M. Nguyen, G. A. Roth et al., “Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the global burden of disease study 2016,” The Lancet. Neurology, vol. 18, no. 5, pp. 439–458, 2019.
[2] M. Goyal, B. K. Menon, W. H. van Zwam et al., “Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials,” The Lancet, vol. 387, no. 10029, pp. 1723–1731, 2016.
[3] S. I. Savitz, J.-C. Baron, M. A. Yenari, N. Sanossian, and M. Fisher, “Reconsidering neuroprotection in the reperfusion era,” Stroke, vol. 48, no. 12, pp. 3413–3419, 2017.
[4] A. Chamorro, U. Dinnagl, X. Urra, and A. M. Planas, “Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation,” The Lancet Neurology, vol. 15, no. 8, pp. 869–881, 2016.
[5] H. A. Seifert and K. R. Pennypacker, “Molecular and cellular immune responses to ischemic brain injury,” Translational Stroke Research, vol. 5, no. 5, pp. 543–553, 2014.
[6] M. Fricker, A. M. Tolkovsky, V. Borutaite, M. Coleman, and G. C. Brown, “Neuronal cell death,” Physiological Reviews, vol. 98, no. 2, pp. 813–880, 2018.
Evidence-Based Complementary and Alternative Medicine 13

[7] K. Shi, D.-C. Tian, Z.-G. Li, A. F. Ducrue, M. T. Lawton, and F.-D. Shi, "Global brain inflammation in stroke," The Lancet Neurology, vol. 18, no. 11, pp. 1058–1066, 2019.

[8] L. Wu, X. Xiong, X. Wu et al., "Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury," Frontiers in Molecular Neuroscience, vol. 13, 2020.

[9] O. A. Harari and J. K. Liao, "NF-κB and innate immunity in ischemic stroke," Annuals of the New York Academy of Sciences, vol. 1207, no. 1, pp. 32–40, 2010.

[10] S. Miyamoto, "Nuclear initiated NF-κB signaling: NEMO and ATM take center stage," Cell Research, vol. 21, no. 1, pp. 116–130, 2011.

[11] D. A. Ridder and M. Schwaninger, "NF-κB signaling in cerebral ischemia," Neuroscience, vol. 158, no. 3, pp. 995–1006, 2009.

[12] R. T. G’Sell, P. M. Gaffney, and D. W. Powell, "Review: A20 binding inhibitor of NF-κB activation 1 is a physiological inhibitor of NF-κB: a molecular switch for inflammation and autoimmunity," Arthritis & Rheumatology, vol. 67, no. 9, pp. 2292–2302, 2015.

[13] A. Ma and B. A. Malyon, "A20: linking a complex regulator of ubiquitination to immunity and human disease," Nature Reviews Immunology, vol. 12, no. 11, pp. 774–785, 2012.

[14] C. Mauro, F. Pacifico, A. Lavorgna et al., "ABIN-1 binds to NEMO/IKKγ and Co-operates with A20 in inhibiting NF-κB," Journal of Biological Chemistry, vol. 281, no. 27, pp. 18482–18488, 2006.

[15] L. Verstrepen, I. Carpentier, K. Verhelst, and R. Beyaert, "ABINs: A20 binding inhibitors of NF-κB and apoptosis signaling," Biochemical Pharmacology, vol. 78, no. 2, pp. 105–114, 2009.

[16] J. Zhou, R. Wu, A. A. High et al., "A20-binding inhibitor of NF-κB (ABIN1) controls toll-like receptor-mediated CCAAT/NF-κB and apoptosis signaling," Proceedings of the National Academy of Sciences, vol. 108, no. 44, pp. E998–E1006, 2011.

[17] S. Oshima, E. E. Turer, J. A. Callahan et al., "ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development," Nature, vol. 457, no. 7231, pp. 906–909, 2009.

[18] Y. Zhang, X. Lei, W. Li et al., "TNIP1 alleviates hepatic ischemia/reperfusion injury via the TLR2/MvydB pathway," Biochemical and Biophysical Research Communications, vol. 501, no. 1, pp. 186–192, 2018.

[19] K. El Bakkouri, A. Wullaert, M. Haegman, K. Heyninck, and R. Beyaert, "Adenoviral gene transfer of the NF-κB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model," Journal of Biological Chemistry, vol. 280, no. 18, pp. 17938–17944, 2005.

[20] E. A. Korte, D. J. Caster, M. T. Barati et al., "ABIN1 determines severity of glomerulonephritis via activation of intrinsic glomerular inflammation," The American Journal of Pathology, vol. 187, no. 12, pp. 2799–2810, 2015.

[21] J. A. Callahan, G. E. Hammer, A. Agelides et al., "Cutting edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells," The Journal of Immunology, vol. 191, no. 2, pp. 535–539, 2013.

[22] K. Peng, Y. Li, C. Lu, and S. Hu, "ABIN-1 protects dendrocytes from lipopolysaccharide-induced inflammatory injury through the inactivation of NF-κB signalling," Clinical and Experimental Pharmacology and Physiology, vol. 47, no. 7, pp. 1212–1220, 2020.

[23] Y. Xing, M. Zhang, W. B. Li, F. Dong, and F. Zhang, "Mechanisms involved in the neuroprotection of electroacupuncture therapy for ischemic stroke," Front Neurosci, vol. 12, p. 929, 2018.

[24] L. Ullóa, S. Quiróz-Gonzalez, and R. Torres-Rosas, "Nerve stimulation: immunomodulation and control of inflammation," Trends in Molecular Medicine, vol. 23, no. 12, pp. 1103–1120, 2017.

[25] J.-Y. Park and U. Namgung, "Electroacupuncture therapy in inflammation regulation: current perspectives," Journal of Inflammation Research, vol. 11, pp. 227–237, 2018.

[26] L. M. Chavez, S. S. Huang, I. MacDonald, J. G. Lin, Y. C. Lee, and Y. H. Chen, "Mechanisms of acupuncture therapy in ischemic stroke rehabilitation: a literature review of basic studies," International Journal of Molecular Sciences, vol. 18, no. 11, Article ID E2270, 2017.

[27] L. Chi, K. Du, D. Liu, Y. Bo, and W. Li, "Electroacupuncture brain protection during ischemic stroke: a role for the parasympathetic nervous system," Journal of Cerebral Blood Flow & Metabolism, vol. 38, no. 3, pp. 479–491, 2017.

[28] M. H. Shen, C. B. Zhang, J. H. Zhang, and P. F. Li, "Electroacupuncture attenuates cerebral ischemia and reperfusion injury in middle cerebral artery occlusion of rat via modulation of apoptosis, inflammation, oxidative stress, and excitotoxicity," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 9438650, 15 pages, 2016.

[29] Z. Jin, J. Liang, J. Wang, and P. E. Kolattukudy, "Delayed brain ischemia tolerance induced by electroacupuncture pretreatment is mediated via MCP-induced protein 1," Journal of Neuroinflammation, vol. 10, no. 63, Article ID 845, 2013.

[30] L. Lan, J. Tao, A. Chen et al., "Electroacupuncture exerts anti-inflammatory effects in cerebral ischemia-reperfusion injured rats via suppression of the TLR4/NF-κB pathway," International Journal of Molecular Medicine, vol. 31, no. 1, pp. 75–80, 2013.

[31] W. Y. Qin, Y. Luo, L. Chen et al., "Electroacupuncture could regulate the NF-κB signaling pathway to ameliorate the inflammatory injury in focal cerebral ischemia/reperfusion model rats," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 924541, 15 pages, 2013.

[32] J. Zhan, W. Qin, Y. Zhang et al., "Upregulation of neuronal zinc finger protein A20 expression is required for electroacupuncture to attenuate the cerebral inflammatory injury mediated by the nuclear factor-kB signaling pathway in cerebral ischemia/reperfusion rats," Journal of Neuroinflammation, vol. 13, no. 1, p. 258, 2016.

[33] J. Jiang, Y. Luo, W. Qin et al., "Electroacupuncture suppresses the NF-κB signaling pathway by upregulating cyclinomatosidase to alleviate inflammatory injury in cerebral ischemia/reperfusion rats," Frontiers in Molecular Neuroscience, vol. 10, p. 363, 2017.

[34] K. Zhang, Q. Zhang, J. Deng et al., "ALK5 signaling pathway by upregulating cylindromatosis to alleviate inflammatory injury in cerebral ischemia/reperfusion rats," Frontiers in Molecular Neuroscience, vol. 10, no. 5, pp. 360, 2019.

[35] X. Han, H. Wu, P. Yin et al., "Electroacupuncture restores hippocampal synaptic plasticity via modulation of 5-HT receptors in a rat model of depression," Brain Research Bulletin, vol. 139, pp. 256–262, 2018.

[36] J. Chen, P. R. Sanberg, Y. Li et al., "Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats," Stroke, vol. 32, no. 11, pp. 2682–2688, 2001.

[37] R. J. Komotar, G. H. Kim, M. E. Sughrue et al., "Neurologic assessment of somatosensory dysfunction following an
experimental rodent model of cerebral ischemia,” *Nature Protocols*, vol. 2, no. 10, pp. 2345–2347, 2007.

[38] J. Agulla, D. Brea, F. Campos et al., “In vivo theranostics at the peri-infarct region in cerebral ischemia,” *Theranostics*, vol. 4, no. 1, pp. 90–105, 2013.

[39] H. Xu, W. Qin, X. Hu et al., “Lentivirus-mediated over-expression of OTULIN ameliorates microglia activation and neuroinflammation by depressing the activation of the NF-kB signaling pathway in cerebral ischemia/reperfusion rats,” *Journal of Neuroinflammation*, vol. 15, no. 1, p. 83, 2018.

[40] S. E. Taylor, C. Morganti-Kossmann, J. Lifshitz et al., “Rod microglia: a morphological definition,” *PLoS One*, vol. 9, no. 5, Article ID e97096, 2014.

[41] H. W. Morrison and J. A. Filosa, “A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion,” *Journal of Neuroinflammation*, vol. 10, p. 4, 2013.

[42] K. Young and H. Morrison, “Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ,” *Journal of Visualized Experiments: JoVE*, vol. 136, Article ID e57648, 2018.

[43] W. Zhu, Y. Ye, Y. Liu et al., “Mechanisms of acupuncture therapy for cerebral ischemia: an evidence-based review of clinical and animal studies on cerebral ischemia,” *Journal of Neuroimmune Pharmacology*, vol. 12, no. 4, pp. 575–592, 2017.

[44] F.-P. Huang, Z.-Q. Wang, D.-C. Wu, G. P. Schielke, Y. Sun, and G.-Y. Yang, “Early NFκB activation is inhibited during focal cerebral ischemia in interleukin-1β-converting enzyme deficient mice,” *Journal of Neuroscience Research*, vol. 73, no. 5, pp. 698–707, 2003.

[45] E. L. Pranski, N. V. Dalal, J. H. Herskowitz et al., “Neuronal RING finger protein 11 (RNF11) regulates canonical NF-kB signaling,” *Journal of Neuroinflammation*, vol. 9, p. 247, 2012.

[46] L. Catrysse, L. Vereecke, R. Beyaert, and G. van Loo, “A20 in inflammation and autoimmunity,” *Trends in Immunology*, vol. 35, no. 1, pp. 22–31, 2014.

[47] I. Gurevich, C. Zhang, P. C. Encarnacao, C. P. Struzynski, S. E. Livings, and B. J. Aneskiевич, “PPARγ and NF-kB regulate the gene promoter activity of their shared repressor, TNIP1,” *Biochim Biophys Acta*, vol. 1819, no. 1, pp. 1–15, 2012.

[48] E. L. Pranski, C. D. Van Sanford, N. V. Dalal et al., “Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain,” *Neuroscience Letters*, vol. 520, no. 1, pp. 104–109, 2012.

[49] B. Puig, S. Brenna, and T. Magnus, “Molecular communication of a dying neuron in stroke,” *International Journal of Molecular Sciences*, vol. 19, no. 9, Article ID 2834, 2018.

[50] Y. Fu, Q. Liu, J. Anrather, and F.-D. Shi, “Immune interventions in stroke,” *Nature Reviews Neuroscience*, vol. 11, no. 9, pp. 524–535, 2015.

[51] S. P. Gadani, J. T. Walsh, J. R. Lukens, and J. Kipnis, “Dealing with danger in the CNS: the response of the immune system to injury,” *Neuron*, vol. 87, no. 1, pp. 47–62, 2015.

[52] L.-y. Ao, Y.-Y. Yan, L. Zhou et al., “Immune cells after ischemic stroke onset: roles, migration, and target intervention,” *Journal of Molecular Neuroscience*, vol. 66, no. 3, pp. 342–355, 2018.

[53] X. Hu, P. Li, Y. Guo et al., “Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia,” *Stroke*, vol. 43, no. 11, pp. 3063–3070, 2012.

[54] D. Amantea, G. Nappi, G. Bernardi, G. Bagetta, and M. T. Corasaniti, “Post-ischemic brain damage: pathophysiology and role of inflammatory mediators,” *FEBS Journal*, vol. 276, no. 1, pp. 13–26, 2009.

[55] F. Wan, X. Niu, Y.-L. Song, and Y.-C. Si, “The role of Chinese herbs and acupuncture on the inflammation reaction after cerebral ischemia,” *Current Pharmaceutical Design*, vol. 22, no. 6, pp. 709–719, 2016.

[56] R. Ma, B. Yuan, J. Du et al., “Electroacupuncture alleviates nerve injury after cerebral ischemia in rats through inhibiting cell apoptosis and changing the balance of MMP-9/TIMP-1 expression,” *Neuroscience Letters*, vol. 633, pp. 158–164, 2016.

[57] Z. X. Chen, Y. Li, X. G. Zhang et al., “Sham electroacupuncture methods in randomized controlled trials,” *Scientific Reports*, vol. 7, Article ID 40837, 2017.

[58] R. Sha, B. Zhang, X. Han et al., “Electroacupuncture alleviates ischemic brain injury by inhibiting the miR-223/NLRP3 pathway,” *Medical Science Monitor*, vol. 25, pp. 4723–4733, 2019.

[59] J. Huang, X. You, W. Liu et al., “Electroacupuncture ameliorating post-stroke cognitive impairments via inhibition of peri-infarct astrogial and microglial/macrophase P2 purinoceptors-mediated neuroinflammation and hyperplasia,” *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, 2017.

[60] Y. Wang, Y. Shen, H. P. Lin, Z. Li, Y. Y. Chen, and S. Wang, “Large-conductance Ca(2+)-activated K(+) channel involvement in suppression of cerebral ischemia/reperfusion injury after electroacupuncture at Shuigou (GV26) acupoint in rats,” *Neural Regeneration Research*, vol. 11, no. 6, pp. 957–962, 2016.